Long-term survival in venous thromboembolic disease: rivaroxaban vs. warfarin - propensity score matching study.
Estefan Ramos-IsazaEduardo Tuta-QuinteroAlirio Rodrigo Bastidas GoyesDiana Diaz-QuijanoCarolina Aponte-MurciaJulian Espitia-AngelDaniel Pinto-BeltranJohan Rincón-HernándezJuan Sánchez-CuellarJesus Pérez-BuenoLuis F Giraldo-CadavidPublished in: BMC pharmacology & toxicology (2023)
In the treatment of VTE, there is no differences on 6 and 12-month survival or a reduction in the occurrence of new thromboembolic events when comparing rivaroxaban to warfarin. However, a lower risk of major bleeding is observed at 12 months with Rivaroxaban.